Oak Hill Bio and Chiesi Group have begun a Phase IIb clinical trial for OHB-607 to prevent bronchopulmonary dysplasia in premature infants across Europe.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
Oak Hill Bio and Chiesi Group have begun a Phase IIb clinical trial for OHB-607 to prevent bronchopulmonary dysplasia in premature infants across Europe.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
We are preparing, please wait
This content is only available for premium members. Please become a paid member to access.
Download AppCurrently, memberships can only be purchased through the app.